INTRODUCTION Living donor transplantation allows a priori scheduling and the recipient can receive immunosuppressive prophylaxis several days before surgery, which is preoperative induction therapy with oral agents. We evaluated the impact of preoperative mycophenolate mofetil on the outcomes of living donor kidney transplantations. MATERIALS AND METHODS In a randomized controlled trial was f...

BACKGROUND AND OBJECTIVES Although the accepted standard of care for induction of lupus nephritis has been cyclophosphamide, recent trials suggest that mycophenolate mofetil may be as or more effective and less toxic. A systematic review and meta-analysis were performed to determine the risk for failure to induce remission of lupus nephritis in patients who were treated with mycophenolate mofet...

Mycophenolic acid has gained widespread acceptance as the antimetabolite of choice in most of the immunosuppressive regimens, thanks to its selective action versus T and B cells. This drug is characterized by a narrow therapeutic index and a well-documented relationship between efficacy (in terms of acute rejection episodes) and exposure to mycophenolic acid (as AUC and C0). For these reasons, ...

BACKGROUND AND OBJECTIVES The optimal maintenance immunosuppressive regimen to improve long-term renal allograft function and graft survival is yet to be determined. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This observational study prospectively compared tacrolimus/sirolimus with tacrolimus/mycophenolate mofetil in renal transplant recipients using a prednisone-free regimen with over 8.5...

background: calcineurin inhibitors (cni) have significantly reduced the incidence of acute rejection. nephrotoxicity however may contribute to long-term allograft dysfunction. mycophenolate mofetil (mmf) may allow cyclosporine (csa) dose reduction without increasing the risk of rejection. methods: in seventy-eight living unrelated kidney transplant patients with renal dysfunction, we studied th...

OBJECTIVE To evaluate whether mycophenolate mofetil, a new immunosuppressive agent, is effective for treating moderate-severe atopic dermatitis (AD). DESIGN In an open-label pilot study, mycophenolate mofetil, 1 g, was given orally twice daily for 4 weeks. At week 5, the dosage was reduced to 500 mg twice daily until study end (week 8). Patients were followed up for 20 weeks. SETTING Univer...

Hirschsprung disease (HSCR) is a partially penetrant oligogenic birth defect that occurs when enteric nervous system (ENS) precursors fail to colonize the distal bowel during early pregnancy. Genetic defects underlie HSCR, but much of the variability in the occurrence and severity of the birth defect remain unexplained. We hypothesized that nongenetic factors might contribute to disease develop...

1. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001;24:645-63. 2. Zolezzi M. Mycophenolate Sodium versus Mycophenolate Mofetil: A Review of Their Comparative Features. Saudi J Kidney Dis Transpl 2005;16:140-45. 3. Selbst MK, Ahrens WA, Robert ME, Friedman A, Proctor DD, Jain D. Spectrum of histologic changes in colonic biop...